Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure

The prognosis for patients with myelodysplastic syndrome with hypomethylating treatment failure (MDS-HTF) has been known to be poor. However, the clinical outcomes and optimal treatment options for secondary AML evolving from MDS-HTF (sAML/MDS-HTF) are not well known. This retrospective analysis was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2013-05, Vol.48 (5), p.678-683
Hauptverfasser:	Shin, S-H, Yahng, S-A, Yoon, J-H, Lee, S-E, Cho, B-S, Eom, K-S, Lee, S, Min, C-K, Kim, H-J, Cho, S-G, Kim, D-W, Lee, J-W, Min, W-S, Park, C-W, Kim, Y-J
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/1904 692/699/1541 692/699/67/1990/283/1897 692/700/565/1436/99 Adolescent Adult Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antimetabolites, Antineoplastic - therapeutic use Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Chemotherapy Clinical outcomes Cytogenetics Evolution Female Health services Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation - methods Humans Internal Medicine Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - surgery Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Multivariate analysis Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - pathology Myelodysplastic Syndromes - surgery original-article Patients Prognosis Public Health Stem cell transplantation Stem Cells Survival Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Treatment Failure Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The prognosis for patients with myelodysplastic syndrome with hypomethylating treatment failure (MDS-HTF) has been known to be poor. However, the clinical outcomes and optimal treatment options for secondary AML evolving from MDS-HTF (sAML/MDS-HTF) are not well known. This retrospective analysis was conducted to evaluate the clinical outcomes and influences of treatment options on survival in 46 consecutive patients with sAML/MDS-HTF. The median OS rates were 1.4 months in the best supportive care group ( n =15) and 9.4 months in the active treatment group ( n =31). One-year OS rates were 13.3% and 36.8%, respectively ( P =0.001). Active treatment ( P
ISSN:	0268-3369 1476-5365
DOI:	10.1038/bmt.2012.214